Agonist-controlled competition of RAR and VDR nuclear receptors for heterodimerization with RXR is manifested in their DNA binding
Journal of Biological Chemistry · 2023-02 · 299 (2) · 102896
DOI: 10.1016/j.jbc.2023.102896 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023-02. Verfasst von Bálint Rehó und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics and Cell Biology, Faculty of Medicine, Doctoral School of Molecular Medicine, University of Debrecen, Debrecen, Hungary. Hauptthemen laut MEDLINE: Receptors, Calcitriol, Retinoid X Receptors, Receptors, Retinoic Acid. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nemzeti Kutatasi Fejlesztesi es Innovacios Hivatal.
Abstract (Originalsprache)
We found previously that nuclear receptors (NRs) compete for heterodimerization with their common partner, retinoid X receptor (RXR), in a ligand-dependent manner. To investigate potential competition in their DNA binding, we monitored the mobility of retinoic acid receptor (RAR) and vitamin D receptor (VDR) in live cells by fluorescence correlation spectroscopy. First, specific agonist treatment and RXR coexpression additively increased RAR DNA binding, while both agonist and RXR were required for increased VDR DNA binding, indicating weaker DNA binding of the VDR/RXR dimer. Second, coexpression of RAR, VDR, and RXR resulted in competition for DNA binding. Without ligand, VDR reduced the DNA-bound fraction of RAR and vice versa, i.e., a fraction of RXR molecules was occupied by the competing partner. The DNA-bound fraction of either RAR or VDR was enhanced by its own and diminished by the competing NR's agonist. When treated with both ligands, the DNA-bound fraction of RAR increased as much as due to its own agonist, whereas that of VDR increased less. RXR agonist also increased DNA binding of RAR at the expense of VDR. In summary, competition between RAR and VDR for RXR is also manifested in their DNA binding in an agonist-dependent manner: RAR dominates over VDR in the absence of agonist or with both agonists present. Thus, side effects of NR-ligand-based (retinoids, thiazolidinediones) therapies may be ameliorated by other NR ligands and be at least partly explained by reduced DNA binding due to competition. Our results also complement the model of NR action by involving competition both for RXR and for DNA sites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biophysics and Cell Biology, Faculty of Medicine, Doctoral School of Molecular Medicine, University of Debrecen, Debrecen, Hungary.
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Princess Maxima Centre for Pediatric Oncology, Utrecht, the Netherlands.
- Section of Molecular Cytology and van Leeuwenhoek Centre for Advanced Microscopy (LCAM), Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Department of Medicine and Biological Chemistry, Johns Hopkins University School of Medicine, Institute f…
- Department of Biophysics and Cell Biology, Faculty of Medicine, Doctoral School of Molecular Medicine, University of Debrecen, Debrecen, Hungary. Electronic address: vamosig@med.unideb.hu.
Förderung
- Nemzeti Kutatasi Fejlesztesi es Innovacios Hivatal
Zitieren
APA
Rehó, B., Fadel, L., Brazda, P., Benziane, A., Hegedüs, É., Sen, P., Gadella, T. W. J., Tóth, K., Nagy, L., & Vámosi, G. (2023). Agonist-controlled competition of RAR and VDR nuclear receptors for heterodimerization with RXR is manifested in their DNA binding. Journal of Biological Chemistry, 299(2), 102896. https://doi.org/10.1016/j.jbc.2023.102896
Vancouver
Rehó B, Fadel L, Brazda P, Benziane A, Hegedüs É, Sen P, et al. Agonist-controlled competition of RAR and VDR nuclear receptors for heterodimerization with RXR is manifested in their DNA binding. Journal of Biological Chemistry. 2023;299(2):102896. doi:10.1016/j.jbc.2023.102896
BibTeX
@article{Reh2023,
author = {Rehó, Bálint and Fadel, Lina and Brazda, Peter and Benziane, Anass and Hegedüs, Éva and Sen, Pialy and Gadella, Theodorus W J and Tóth, Katalin and Nagy, László and Vámosi, György},
title = {Agonist-controlled competition of RAR and VDR nuclear receptors for heterodimerization with RXR is manifested in their DNA binding},
journal = {Journal of Biological Chemistry},
year = {2023},
volume = {299},
number = {2},
pages = {102896},
doi = {10.1016/j.jbc.2023.102896}
}
EUVIMED